TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06757153
Drug: NRG-103
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.
Study: NCT06194617
Drug: Direct oral anticoagulant
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
Study: NCT06761339
Drug: Prospan cough Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.
Study: NCT06767150
Drug: a second infusion of ZOL when crosslaps levels reach 300 pg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12
Study: NCT06763094
Drug: Calcium dobesilate (Doxium)
Normalized name: calcium dobesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is unique because Calcium Dobesilate is not a hormonal agent and does not carry the risks associated with hormonal therapies, such as potential impact on fertility or long-term endocrine effects. Additionally, it may be more suitable for patients who cannot tolerate hormonal treatments due to contraindications such as previous thrombotic events or risk factors for thrombosis.
Study: NCT06771921
Drug: GEN1078
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days.
Study: NCT06773221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, qd, for 72 weeks
Study: NCT06323837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match.
Study: NCT05289037
Drug: AS03
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03 oil-in-water emulsion adjuvant.
Study: NCT04715568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken orally
Study: NCT04674241
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT06779045
Drug: AK-1286
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.
Study: NCT05142267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Study: NCT05013008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
Study: NCT04760717
Drug: Spironolactone Pill
Normalized name: spironolactone Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
Study: NCT06115733
Drug: Fruquintinib、Capecitabine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression.
Study: NCT05874063
Drug: Thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboprophylaxis in addition of the standard chemotherapy
Study: NCT05318794
Drug: Doxorubicin and Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressurised intraperitoneal aerosol chemotherapy
Study: NCT05934513
Drug: GFH009
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
Study: NCT06752603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT06765265
Drug: Rosuvastatin 20 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg / Day for 24 weeks
Study: NCT06768255
Drug: Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT
Normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone Acetate（II）
Study: NCT06768255
Drug: Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000 mg
Study: NCT00929461
Drug: Lipovenoes® 10% and Omegaven®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
Study: NCT06343753
Drug: Opioid free analgesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: o Group OFA: Opioid free anesthesia Analgesia will be provided by syringe containing ketamine, Lidocaine and Dexmedetomidine in induction and maintenance according to lean body weight (LBW).
Study: NCT06343753
Drug: Opioid based Anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: o Group TBA: Traditional balanced anesthesia Analgesia will be provided by fentanyl in induction and maintenance according to Ideal Body Weight (IBW)
Study: NCT06263452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated sugar pill to visually look identical to the experimental condition.
Study: NCT06768658
Drug: TAK-951 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 placebo-matching subcutaneous injection.
Study: NCT05895201
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg IV over 1 hour on days +3 and +4
Study: NCT05191004
Drug: NUV-422
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUV-422 is an investigational drug for oral dosing.
Study: NCT06045910
Drug: ALETA-001
Normalized name: DIOSCOREA ALATA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALETA-001 will be administered intravenously (IV) every two weeks.
Study: NCT06247995
Drug: [68Ga]Ga-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.
Study: NCT06247995
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a chemotherapy drug.
Study: NCT06758037
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W
Study: NCT06765603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06776432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06776432
Drug: SASS-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06777485
Drug: Anti-Tumor Drugs
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Study: NCT06776692
Drug: Qdenga
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Dengue vaccine and blood sample collection
Study: NCT06274294
Drug: CT-P13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment.
Study: NCT04981717
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC for a total of 5 administrations
Study: NCT04686955
Drug: Xiao-Xian-Gui-Fu-Tang
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
Study: NCT06581302
Drug: Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.
Study: NCT06306300
Drug: Non- specialist - Epclusa 400Mg-100Mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
Study: NCT05309811
Drug: Routine IOP-lowering medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications prescribed for IOP control by glaucoma specialists in the outpatient.
Study: NCT05504278
Drug: IBI351
Approvals — FDA: no, EMA: no, PMDA: no
Description: recommended dose, po
Study: NCT06775314
Drug: Combination cream
Normalized name: SUNSCREEN-35 PABA-FREE COMBINATION CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic acid will be given to subjects to be applied every morning, evening and night in group 2
Study: NCT06775314
Drug: spot cream
Normalized name: Cold Spot
Approvals — FDA: no, EMA: no, PMDA: no
Description: spot cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol, will be given to subjects to be applied every morning and evening in group 2
Study: NCT06775314
Drug: placebo cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cleanser will be given to subjects to be applied every morning, evening and night in group 1
Study: NCT06775314
Drug: placebo cream combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream combination will be given to subjects to be applied every morning, evening and night in group 1
Study: NCT06775314
Drug: placebo spot cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo spot cream will be given to subjects to be applied every morning and evening in group 1
Study: NCT06775522
Drug: YHP2205
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug: YHP2205 Comparator: YHR2401
Study: NCT06775522
Drug: YHR2401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug: YHP2205 Comparator: YHR2401
Study: NCT05436418
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
Study: NCT06771245
Drug: SYH9056 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO once daily
Study: NCT06771427
Drug: Chinese herbal tea TBDESJS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.
Study: NCT06770933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
Study: NCT06772454
Drug: Antitumor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received suglizumab + paclitaxel + carboplatin:~Suglizumab 1200 mg IV Q3W Paclitaxel (albumin-bound) 100 mg/m2 IV, D1, 8, 15, Q3W Carboplatin AUC=5 mg/mL/min IV Q3W A total of 4 administration cycles were given, and Suglizumab 1200 mg IV Q3W was maintained after 4 administration cycles
Study: NCT06778304
Drug: Gonal F
Normalized name: Gonal F
Approvals — FDA: no, EMA: no, PMDA: no
Description: The reference formulation is the recombinant human follicle-stimulating hormone injection (Gonal-f®) originally developed and produced by Merck Serono
Study: NCT06778304
Drug: jzb30
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test formulation is the recombinant human follicle-stimulating hormone injection (code: JZB30) produced by Shanghai Jingze Biotechnology Co., Ltd./Chengdu Jingze Biopharmaceutical Co., Ltd.
Study: NCT05242744
Drug: [18F]FluorThanatrace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
Study: NCT06778902
Drug: R-GemOx
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
Study: NCT06760702
Drug: AUR109 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUR109 200mg (once daily)
Study: NCT06760702
Drug: AUR109 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUR109 300mg once daily
Study: NCT06766825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion.
Study: NCT06771323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05651594
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05651594
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06778603
Drug: a targeted probe B7H3-IRDye800CW
Approvals — FDA: no, EMA: no, PMDA: no
Description: B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.
Study: NCT06739720
Drug: LingZhi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract
Study: NCT06751394
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy
Study: NCT06739759
Drug: Modified Agonist protocol for IVF with additive treatments as HCQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: giving additive drugs to agonist protocolas HCQ
Study: NCT06753864
Drug: Test (T)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.
Study: NCT05302986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with intravenous injection of Placebo (0.9% sodium chloride). A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes during shoulder surgery.
Study: NCT05238233
Drug: Proparacaine Hydrochloride
Normalized name: Proparacaine Hydrochloride
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop will be given to participants
Study: NCT06762964
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will take 10mg placebo tablet once daily for 24 weeks
Study: NCT06776861
Drug: PD-1 / PD-L1 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.
Study: NCT03586089
Drug: Inactive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of inactive placebo prepared in 250 ml D5W).
Study: NCT06105021
Drug: AFNT-211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engineered TCR T-Cell
Study: NCT06727552
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration
Study: NCT06033833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Solution: by subcutaneous injection (SCI)
Study: NCT06775093
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months
Study: NCT06770881
Drug: JSKN033
Approvals — FDA: no, EMA: no, PMDA: no
Description: JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle
Study: NCT06771050
Drug: Antibiotic Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention: Backbone antibiotic therapy only depends on the organism and is detailed in the protocol.~Intervention: Backbone antibiotic therapy plus rifampicin. Dosage 600-900mg per day orally for as long as oral antibiotic treatment continues, but not more than 12 weeks. Prescribed according to local recommended practices and dosed as per local therapeutic guidelines.
Study: NCT06771050
Drug: Antibiotic Duration Part B - Two stage revision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Arm: Extended prophylaxis for 12 weeks after the 2nd stage revision surgery.~Intervention Arm: No extended antibiotic prophylaxis after the 2nd stage revision surgery.~Antibiotic choice by treating team with reference to the original causative organism(s), susceptibility and patient tolerability.
Study: NCT06774131
Drug: UGN-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-104 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the UUT.
Study: NCT06774235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of placebo in the same condition of experimental traitment
Study: NCT06774963
Drug: LNCB74
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
Study: NCT06771115
Drug: VTX3232 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTX3232 Dose A
Study: NCT06771115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06770426
Drug: carbogen with or without phenyleprhine
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes. All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Study: NCT06771063
Drug: WXSH0102/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer WXSH0102 tablets/placebo orally.
Study: NCT06770439
Drug: IBI343
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate
Study: NCT06775743
Drug: ORIENT-31 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus bevacizumab plus platinum-doublet chemotherapy